Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions [PDF]
Frontiers in Immunology, 2020 Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease?
Elizabeth Krieger, Amir Ahmed Toor
doaj +3 more sources
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease [PDF]
Haematologica, 2015 Effective pharmacological strategies employed in allogeneic hematopoietic cell transplantation should prevent serious chronic graft-versus-host disease and facilitate donor-recipient immune tolerance.
Joseph Pidala +15 more
doaj +3 more sources
Body Composition Assessment Provides Prognostic Information in Patients With Cancer Affected by Chronic Graft vs. Host Disease [PDF]
Journal of Cachexia, Sarcopenia and MuscleBackground Additional tools are needed to assess mortality risk among patients with cancer. Patients with chronic graft vs. host disease (cGVHD) after allogeneic haematopoietic cell transplantation (HCT) represent a high‐risk cancer population with ...
Asmita Mishra +8 more
doaj +2 more sources
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation [PDF]
Haematologica, 2014 The study is a randomized phase II trial investigating graft-versus-host disease prophylaxis after non-myeloablative (90 mg/m2 fludarabine and 2 Gy total body irradiation) human leukocyte antigen matched unrelated donor transplantation.
Brian Kornblit +16 more
doaj +4 more sources
AAV-mediated expression of HLA-G for the prevention of experimental ocular graft vs. host disease [PDF]
Molecular Therapy: Methods & Clinical Development, 2023 Ocular graft versus host disease (OGvHD) develops after allogeneic hematopoietic stem cell transplantation (HSCT) and manifests as ocular surface inflammatory disease.
Jacob P. Nilles +8 more
doaj +2 more sources
Acute graft-vs-host disease [PDF]
Experimental Hematology, 2001 Acute graft-vs-host disease (GVHD) is a major obstacle to safe allogeneic hematopoietic stem cell transplantation (HSCT), leading to a significant morbidity and mortality. GVHD occurs when transplanted donor T lymphocytes react to foreign host cells. It causes a wide variety of host tissue injuries.
Hakan Goker +2 more
openaire +4 more sources
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report [PDF]
Journal of Hematology & Oncology, 2016 Background Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative in a variety of hematological malignancies. Graft-vs.-host disease (GvHD) remains a life-threatening complication.
Enrico Maffini +10 more
doaj +2 more sources
Acetabular Insufficiency Fractures in the Setting of Graft vs Host Disease: A Report of Two Cases [PDF]
Arthroplasty Today, 2021 We report a case series of 2 patients with unilateral acetabular insufficiency fractures who received allogeneic peripheral blood stem cell transplantation for hematologic malignancies complicated by chronic graft vs host disease. These were managed with
Warren Nielsen, BS, Kathryn Schabel, MD
doaj +2 more sources
Activated CD4 + T lymphocyte is a potential biomarker for acute graft-vs.-host disease after hematopoietic stem cell transplantation in children with transfusion-dependent β-thalassemia [PDF]
Frontiers in Pediatrics, 2022 BackgroundAcute graft-vs.-host disease (aGVHD) is still one of the most common and life-threatening complications of allogeneic hematopoietic stem cell transplantation (HSCT).
Ken Huang, Jianming Luo
doaj +2 more sources
Stem Cell Transplantation As A Dynamical System: Are Clinical Outcomes Deterministic? [PDF]
Frontiers in Immunology (2014). 5:613, 2014 Outcomes in stem cell transplantation (SCT) are modeled using probability theory. However the clinical course following SCT appears to demonstrate many characteristics of dynamical systems, especially when outcomes are considered in the context of immune reconstitution.
Buck, Gregory A +16 more
arxiv +5 more sources